- Home
- RIGL vs IVR Comparison
RIGL vs IVR Comparison
Compare RIGL & IVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- IVR
- Stock Information
- Founded
- RIGL 1996
- IVR 2008
- Country
- RIGL United States
- IVR United States
- Employees
- RIGL N/A
- IVR N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- IVR Real Estate Investment Trusts
- Sector
- RIGL Health Care
- IVR Real Estate
- Exchange
- RIGL Nasdaq
- IVR Nasdaq
- Market Cap
- RIGL 537.6M
- IVR 494.7M
- IPO Year
- RIGL 2000
- IVR 2009
- Fundamental
- Price
- RIGL $29.48
- IVR $7.47
- Analyst Decision
- RIGL Buy
- IVR Hold
- Analyst Count
- RIGL 5
- IVR 2
- Target Price
- RIGL $38.20
- IVR $7.50
- AVG Volume (30 Days)
- RIGL 492.6K
- IVR 1.9M
- Earning Date
- RIGL 11-04-2025
- IVR 10-30-2025
- Dividend Yield
- RIGL N/A
- IVR 18.21%
- EPS Growth
- RIGL N/A
- IVR N/A
- EPS
- RIGL 5.43
- IVR 0.32
- Revenue
- RIGL $267,921,000.00
- IVR $59,701,000.00
- Revenue This Year
- RIGL $59.93
- IVR $273.10
- Revenue Next Year
- RIGL N/A
- IVR $0.75
- P/E Ratio
- RIGL $5.44
- IVR $23.54
- Revenue Growth
- RIGL 105.62
- IVR 1793.56
- 52 Week Low
- RIGL $13.57
- IVR $5.86
- 52 Week High
- RIGL $43.72
- IVR $9.06
- Technical
- Relative Strength Index (RSI)
- RIGL 46.18
- IVR 51.48
- Support Level
- RIGL $29.30
- IVR $7.10
- Resistance Level
- RIGL $30.94
- IVR $7.38
- Average True Range (ATR)
- RIGL 1.26
- IVR 0.14
- MACD
- RIGL 0.38
- IVR 0.02
- Stochastic Oscillator
- RIGL 53.61
- IVR 69.90
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About IVR INVESCO MORTGAGE CAPITAL INC
Invesco Mortgage Capital Inc is a REIT that invests, finances, and manages residential and commercial mortgage-backed securities and mortgage loans. The company's portfolio consists of residential mortgage-backed securities (RMBS) that are guaranteed by a U.S. government agency such as the Government National Mortgage Association, or a federally chartered corporation such as the Federal National Mortgage Association or the Federal Home Loan Mortgage Corporation; Commercial mortgage-backed securities (CMBS) that are not guaranteed by a U.S. government agency or a federally chartered corporation; RMBS that are not guaranteed by a U.S. government agency or a federally chartered corporation; and other real estate-related financing arrangements.